P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer

• Sponsor: Hossam Hassan Aly Hassan El Sokkary (Other)
• Overall Status: Completed
• CT.gov ID: NCT05542940
• Collaborator: (none)
• Enrollment: 100
• Location: 1
• Actual Duration (Months): 32
• Patients Per Site Per Month: 3.1

Study Details

Study Description

Brief Summary

Objective: Calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types and grading.

Patients and methods:

100 cases of endometrial cancer will be included in the study, recruited from Alexandria university hospital gyne-oncology unit. Surgical staging, histopathological examination and immunohistochemistry of p53 were done to all cases to calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types, grading.

Keywords: P53 immunohistochemistry, endometrial cancer, clinicopathological relation.

Condition or Disease	Intervention/Treatment	Phase
Endometrial Cancer	Other: p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading

Study Design

• Study Type: Observational
• Actual Enrollment: 100 participants
• Observational Model: Case-Only
• Time Perspective: Cross-Sectional
• Official Title: P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer and Its Relation With Disease Stages, Pathological Types and Grading
• Actual Study Start Date: Jan 1, 2020
• Actual Primary Completion Date: Aug 31, 2022
• Actual Study Completion Date: Aug 31, 2022

Outcome Measures

Primary Outcome Measures

1. p53 immunohistochemistry [1 month]

   Incidence of abnormal staining of p53 in endometrial cancer

2. Relation of p53 abnormal staining with disease stages [1month]

   Relation of p53 abnormal staining with disease stages

3. Relation of p53 abnormal staining with disease pathological types [1 month]

   Relation of p53 abnormal staining with disease pathological types

4. Relation of p53 abnormal staining with disease pathological grades [1 month]

   Relation of p53 abnormal staining with disease pathological grades

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: Female

Inclusion Criteria:

• endometrial cancer patients

Exclusion Criteria:

• patients unfit for surgery

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hossam Hassan El Sokkary	Alexandria		Egypt

Sponsors and Collaborators

• Hossam Hassan Aly Hassan El Sokkary

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hossam Hassan Aly Hassan El Sokkary, Associate professor, Alexandria University
• ClinicalTrials.gov Identifier: NCT05542940
• Other Study ID Numbers: SOKKARY9
• First Posted: Sep 16, 2022
• Last Update Posted: Sep 16, 2022
• Last Verified: Sep 1, 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Endometrial Neoplasms

Study Results

No Results Posted as of Sep 16, 2022